Open Access

VIEWPOINT

MSCs derived extracellular vesicles as a therapeutic paragon for neurodegenerative disorders: A viewpoint

YASHVI SHARMA¹, SHARDA RAY², SUJATA MOHANTY^1,*

1 Stem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), All India Institute of Medical Sciences, New Delhi, India
2 Jawaharlal Nehru Medical College, Karnataka, India

* Address correspondence to: Sujata Mohanty, drmohantysujata@gmail. com

BIOCELL 2022, 46(6), 1435-1438. https://doi.org/10.32604/biocell.2022.018612

Received 05 August 2021; Accepted 08 October 2021; Issue published 07 February 2022

Abstract

Neurodegenerative disorders are a vicious woe to the public health and wellness. Uncertainty in their underlying causes, lack of effective biomarkers for their early detection, existence of only supportive therapy, and their ever rising incidence creates an unmatched need for targeted therapies. Mesenchymal Stem Cells (MSCs) have found to be promising candidates for regenerative and remedial therapy in neurodegenerative disorders, however several biological risks and practical issues impede in their translational utility. Deriving from MSCs are certain Extracellular Vesicles (EVs), which aid in the paracrine action of MSCs and have lately gained the scientific interest for their implacability in diverse set ups. Their cargo is of utmost importance and is being explored in various different diseases like heart diseases, neuronal diseases, respiratory diseases and hepatic diseases. They thereby hold the position of a likely prospective remedial candidate for therapy against neurodegenerative disorders.

---

Keywords

---